Search Results

There are 7394 results for: content related to: Parasite maturation and host serum iron influence the labile iron pool of erythrocyte stage Plasmodium falciparum

  1. You have free access to this content
    Oral deferiprone for iron chelation in people with thalassaemia

    Intervention Review

    The Cochrane Library

    Sheila A Fisher, Susan J Brunskill, Carolyn Doree, Onima Chowdhury, Sarah Gooding and David J Roberts

    Published Online : 21 AUG 2013, DOI: 10.1002/14651858.CD004839.pub3

  2. You have free access to this content
    Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia

    Intervention Review

    The Cochrane Library

    Sheila A Fisher, Susan J Brunskill, Carolyn Doree, Sarah Gooding, Onima Chowdhury and David J Roberts

    Published Online : 21 AUG 2013, DOI: 10.1002/14651858.CD004450.pub3

  3. Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia

    Journal of Paediatrics and Child Health

    Volume 47, Issue 11, November 2011, Pages: 812–817, Saumya Shekhar Jamuar, Angeline Hwei Meeng Lai, Ah Moy Tan, Mei Yoke Chan, Ee Shien Tan and Ivy Swee Lian Ng

    Version of Record online : 9 SEP 2011, DOI: 10.1111/j.1440-1754.2011.02031.x

  4. Randomized, Blinded, Placebo- and Positive-Controlled Crossover Study to Determine the Effect of Deferiprone on the QTc Interval in Healthy Subjects

    Clinical Pharmacology in Drug Development

    Caroline Fradette, Anna Rozova, Anne Stilman, Yu Chung Tsang, Mark J. Allison and Fernando Tricta

    Version of Record online : 10 APR 2017, DOI: 10.1002/cpdd.352

  5. You have free access to this content
    Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells

    Journal of Neurochemistry

    Volume 105, Issue 6, June 2008, Pages: 2466–2476, Francisco Molina-Holgado, Alessandra Gaeta, Paul T. Francis, Robert J. Williams and Robert C. Hider

    Version of Record online : 10 MAR 2008, DOI: 10.1111/j.1471-4159.2008.05332.x

  6. The fenton activity of iron(III) in the presence of deferiprone

    Journal of Pharmaceutical Sciences

    Volume 97, Issue 4, April 2008, Pages: 1454–1467, Lakshmi D. Devanur, Hendrik Neubert and Robert C. Hider

    Version of Record online : 27 AUG 2007, DOI: 10.1002/jps.21039

  7. You have free access to this content
    UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers

    British Journal of Clinical Pharmacology

    Volume 65, Issue 6, June 2008, Pages: 908–916, Lie Michael George Limenta, Totsapol Jirasomprasert, Jeeranut Tankanitlert, Saovaros Svasti, Prapin Wilairat, Udom Chantharaksri, Suthat Fucharoen and Noppawan Phumala Morales

    Version of Record online : 3 MAR 2008, DOI: 10.1111/j.1365-2125.2008.03103.x

  8. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy

    European Journal of Haematology

    Volume 85, Issue 5, November 2010, Pages: 430–438, Annita Kolnagou, Marios Kleanthous and George J. Kontoghiorghes

    Version of Record online : 16 JUL 2010, DOI: 10.1111/j.1600-0609.2010.01499.x

  9. Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis

    Pediatric Blood & Cancer

    Volume 61, Issue 5, May 2014, Pages: 879–884, Mohssen Elalfy, Yasser A. Wali, Mohamad Qari, Ghazi Al Damanhouri, Youssef Al-Tonbary, Dilek Yazman, Zakaria Al Hawsawi, Zeynep Karakas, Yurdanur Kilinc, M. Akif Yesilipek, Mohamed Badr, Usama Elsafy, Mostafa Salama, Yousryeia Abdel Rahman, Shebl Shebl, Anne Stilman, Noemi Toiber Temin and Fernando Tricta

    Version of Record online : 30 DEC 2013, DOI: 10.1002/pbc.24920

  10. Iron-chelating agents for treating malaria

    Intervention Review

    The Cochrane Library

    Helen J Smith and Martin M Meremikwu

    Published Online : 22 APR 2003, DOI: 10.1002/14651858.CD001474

  11. Deferiprone in Friedreich ataxia: A 6-Month randomized controlled trial

    Annals of Neurology

    Volume 76, Issue 4, October 2014, Pages: 509–521, Massimo Pandolfo, Javier Arpa, Martin B. Delatycki, Kim Hanh Le Quan Sang, Caterina Mariotti, Arnold Munnich, Irene Sanz-Gallego, Geneieve Tai, Mark A. Tarnopolsky, Franco Taroni, Michael Spino and Fernando Tricta

    Version of Record online : 30 AUG 2014, DOI: 10.1002/ana.24248

  12. You have free access to this content
    Safety profile of the oral iron chelator deferiprone: a multicentre study

    British Journal of Haematology

    Volume 108, Issue 2, February 2000, Pages: 305–312, Cohen, Galanello, Piga, DiPalma, Vullo and Tricta

    Version of Record online : 24 DEC 2001, DOI: 10.1046/j.1365-2141.2000.01866.x

  13. You have full text access to this OnlineOpen article
    Deferiprone-induced agranulocytosis: 20 years of clinical observations

    American Journal of Hematology

    Volume 91, Issue 10, October 2016, Pages: 1026–1031, Fernando Tricta, Jack Uetrecht, Renzo Galanello, John Connelly, Anna Rozova, Michael Spino and Jan Palmblad

    Version of Record online : 4 AUG 2016, DOI: 10.1002/ajh.24479

  14. Development of a fast LC-MS/MS assay for the determination of deferiprone in human plasma and application to pharmacokinetics

    Biomedical Chromatography

    Volume 26, Issue 12, December 2012, Pages: 1575–1581, Ta-Shu Song, Yow-Wen Hsieh, Ching-Tien Peng, Cheng-Hsiung Liu, Tai-Lin Chen and Mann-Jen Hour

    Version of Record online : 27 MAR 2012, DOI: 10.1002/bmc.2734

  15. Peripheral blood haematopoietic progenitor cells in patients with beta thalassaemia major receiving desferrioxamine or deferiprone as chelation therapy

    European Journal of Haematology

    Volume 78, Issue 1, January 2007, Pages: 48–51, Efthimia Vlachaki, Elissavet Ioannidou-Papagiannaki, Konstantinos Tziomalos, Styliani Haralambidou-Vranitsa, Vassilios Perifanis, Ioannis Klonizakis and Miranda Athanassiou-Metaxa

    Version of Record online : 17 OCT 2006, DOI: 10.1111/j.1600-0609.2006.00773.x

  16. You have free access to this content
    Deferiprone (GPO-L-ONE®) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand

    American Journal of Hematology

    Volume 88, Issue 4, April 2013, Pages: 251–260, Vip Viprakasit, Issarang Nuchprayoon, Ampaiwan Chuansumrit, Kitti Torcharus, Bunchoo Pongtanakul, Jiraporn Laothamatas, Somdet Srichairatanakool, Julaporn Pooliam, Siriwat Supajitkasem, Prapat Suriyaphol, Voravarn S. Tanphaichitr and Soodsarkorn Tuchinda

    Version of Record online : 5 MAR 2013, DOI: 10.1002/ajh.23386

  17. You have free access to this content
    Oral iron chelation therapy for thalassaemia: an uncertain scene

    British Journal of Haematology

    Volume 111, Issue 1, October 2000, Pages: 2–5, M. J. Pippard and D. J. Weatherall

    Version of Record online : 4 AUG 2008, DOI: 10.1111/j.1365-2141.2000.02406.x

  18. Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count

    European Journal of Haematology

    Volume 92, Issue 4, April 2014, Pages: 337–340, Amal M. El-Beshlawy, Mohsen S. El-Alfy, Teny T. Sari, Lee L. Chan and Fernando Tricta

    Version of Record online : 30 JAN 2014, DOI: 10.1111/ejh.12241

  19. Long-Term Trials of Deferiprone in Cooley's Anemia

    Annals of the New York Academy of Sciences

    Volume 850, Issue 1, June 1998, Pages: 217–222, NANCY F. OLIVIERI and GARY M. BRITTENHAM

    Version of Record online : 7 FEB 2006, DOI: 10.1111/j.1749-6632.1998.tb10477.x

  20. Distal ulnar changes in children with thalassemia and deferiprone related arthropathy

    Pediatric Blood & Cancer

    Volume 60, Issue 12, December 2013, Pages: 1957–1962, Rajni Sharma, Rama Anand, Jagdish Chandra, Anju Seth, Harish Pemde and Varinder Singh

    Version of Record online : 13 AUG 2013, DOI: 10.1002/pbc.24678